Author: Jane Edwards|| Date Published: August 10, 2016
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
IAVI will work with NIH™s National Institute of Allergy and Infectious Diseases to characterize and produce HIV envelope protein immunogens, IAVI said Tuesday.
NIAID-backed scientists designed such immunogens in order to develop vaccine candidates that work to generate immune response against HIV infection and facilitate the evaluation of such experimental vaccines in human clinical trials.
Mark Feinberg, IAVI president and CEO, said IAVI is pleased to provide product development services to NIAID in support of its AIDS vaccine development initiatives.
IAVI is a two-decade-old nonprofit organization that aims to advance AIDS vaccine research and development programs through collaboration with government agencies, pharmaceutical firms, hospitals and universities in 25 countries.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
The International AIDS Vaccine Initiative has received a potential seven-year, $98 million contract from the National Institutes of Health to support the agency™s efforts to develop a vaccine against the disease.
